Showing 9161-9170 of 20379 results for "".
- Study Shows liraglutide Results in Increased Insulin Sensitivity Independent of Weight Losshttps://reachmd.com/news/study-shows-liraglutide-results-in-increased-insulin-sensitivity-independent-of-weight-loss/2456767/by Jill Clendening A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type
- GLP-1 RAs and Substance Use Disorders: Findings from a Veteran Cohorthttps://reachmd.com/news/glp-1-ras-substance-use-disorder/2485984/In a large U.S. cohort of veterans with type 2 diabetes, initiation of GLP‑1 receptor agonists was associated with a lower risk of developing sev
- Therapeutic Plasma Exchange in HELLP Syndrome: Emerging Insights and Clinical Applicationshttps://reachmd.com/news/therapeutic-plasma-exchange-in-hellp-syndrome-emerging-insights-and-clinical-applications/2485007/Therapeutic plasma exchange produced rapid clinical reversal in a critically ill postpartum patient with refractory thrombotic microangiopathy/HELLP,
- AI-Powered Retinal Imaging Enhances Early Detection of Diabetic Retinopathyhttps://reachmd.com/news/ai-powered-retinal-imaging-enhances-early-detection-of-diabetic-retinopathy/2471754/A Breakthrough in Automated Eye Disease Diagnosis A research team from Skoltech, the University of Sharjah, and the AIRI Institute has developed an AI-powered system to analyze retinal images, potentially transforming how dia
- Balancing Benefits and Risks: Ozempic's Impact on Health Beyond Diabeteshttps://reachmd.com/news/balancing-benefits-and-risks-ozempics-impact-on-health-beyond-diabetes/2471012/What's New New findings highlight Ozempic's dual role in enhancing cardiovascular health while posing gastrointestinal challenges. Significance Understanding both the benefits and risks is essential for clinicians in making informed treatment decisio
- Heart Organoids Simulate Pregestational Diabetes-Induced Congenital Heart Diseasehttps://reachmd.com/news/heart-organoids-simulate-pregestational-diabetes-induced-congenital-heart-disease/2457114/High magnification confocal image of cardiomyocytes in the myocardial tissue of an organoid. Notice the banded structure of sarcomeres (the contracting units of the heart). Red: cardiomyo
- Evaluating the Impact of Added Sugars in US Infant Formula on Baby Healthhttps://reachmd.com/news/evaluating-the-impact-of-added-sugars-in-us-infant-formula-on-baby-health/2471316/Assessing How Early Sugar Exposure Shapes Long-Term Health Outcomes This article explores concerns over high levels of added sugar in US infant formula, examining evidence that links early exposure to added sugars with an increased risk of obesity, type 2 diabetes,
- GLP‑1 RAs Plus Healthy Lifestyle Linked to Lower MACE Risk in T2Dhttps://reachmd.com/news/glp1-ras-plus-healthy-lifestyle-linked-to-lower-mace-risk-in-t2d/2485846/In adults with type 2 diabetes, an observational cohort analysis in which GLP‑1 receptor agonists use plus ad
- HER2 Amplification Extends Across Tumor Types, Highlighting New Opportunities for Precision Oncologyhttps://reachmd.com/news/her2-amplification-extends-across-tumor-types-highlighting-new-opportunities-for-precision-oncology/2486472/Key Takeaways HER2 amplification was identified in 5.7% of nearly 90,000 solid tumors in Japan, extending well be
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://reachmd.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk